Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 5/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353903 | 1.00 | SRC (0.48) | SRCKMT2APARP1DHFRPDE3B | |
| SCHEMBL30353891 | 0.86 | SRC (0.45) | SRCKMT2APARP1DHFRPDE3B | |
| SCHEMBL20546993 | 0.86 | SRC (0.45) | SRCKMT2APARP1DHFRPDE3B | |
| SCHEMBL6912439 | 0.86 | SRC (0.45) | SRCKMT2APARP1DHFRNPC1 | |
| SCHEMBL15680657 | 0.83 | SRC (0.42) | SRCKMT2APARP1DHFRPDE3B | |
| SCHEMBL1468319 | 0.82 | TNF (0.46) | SRCKMT2APARP1DHFRALDH1A1 | |
| SCHEMBL29609262 | 0.77 | PDE3B (0.50) | SRCKMT2APARP1PDE3BPDE3A | |
| SCHEMBL615784 | 0.77 | PDE3B (0.50) | SRCKMT2APARP1PDE3BPDE3A | |
| SCHEMBL13659569 | 0.77 | PARP1 (0.50) | SRCKMT2APARP1SMN1; SMN2PDPK1 | |
| SCHEMBL15710544 | 0.76 | PARP1 (0.44) | SRCKMT2APARP1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110573505-B | C 5 -anilinoquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-3615522-B1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-08-04 | — | — | EP | disclosed |
| US-10829479-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2020-11-10 | — | — | US | disclosed |
| EP-3615522-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca (SE) | 2020-03-04 | — | — | EP | disclosed |
| CN-110573505-A | C5-anilinoquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20190263787-A1 | C5-anilinoquinazoline Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2019-08-29 | — | — | US | disclosed |
| US-10273227-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-04-30 | — | — | US | disclosed |
| WO-2018197642-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | WO | disclosed |
| US-20180312490-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | US | disclosed |
| CN-102942529-B | 4-(4-substituted piperazine)-5,6,7-trialkoxy quinazoline type compound as well as preparation method and application of 4-(4-substituted piperazine)-5,6,7-trialkoxy quinazoline type compound | UNIV GUIZHOU | 2015-06-24 | — | — | CN | disclosed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| WO-2011056740-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263787-A1 | C5-anilinoquinazoline Compounds and Their Use in Treating Cancer | KIT, C5, C9 | SRC 2261/4885KMT2A 882/4885PARP1 158/4885 |
| US-20180312490-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | KIT, C5, C9 | SRC 2261/4885KMT2A 882/4885PARP1 158/4885 |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | NQO2, PRMT7, QDPR | SRC 3782/4885KMT2A 2472/4885PARP1 612/4885 |
| US-10829479-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | KIT, C5, C9 | SRC 2261/4885KMT2A 882/4885PARP1 158/4885 |
| US-10273227-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | KIT, C5, C9 | SRC 2261/4885KMT2A 882/4885PARP1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.